Registered Members Login:
   
Forgotten Your Details? Click Here To Recover +
Welcome To The ShareCafe Community - Talk Shares And Take Stock With Smart Investors - New Here? Click To Register >

  
 
  
Reply to this topic

EBO, EBOS GROUP LIMITED
nipper
post Posted: Oct 15 2019, 09:49 AM
  Quote Post


Posts: 6,199
Thanks: 2199


QUOTE
Buying into the Australian and New Zealand medical device sector following the strategic acquisition of the LMT (“Life. Movement. Technology.”) and National Surgical businesses.

The acquisition provides EBOS with an initial entry point and strong platform for growth into the A$8 billion Australian and New Zealand medical devices sector.

LMT and National Surgical were co-founded by Jon Mills and Kerry Lawford and over the last 24 years have built a strong presence in Australia and New Zealand providing products and services to the Orthopaedic, Spine, Neuro, ENT, Plastics and most recently the Sports Medicine community. The businesses have developed a niche in bringing innovative specialty products, produced by original equipment manufacturers (OEM’s), into Australia, New Zealand and the Pacific region.

EBOS Chief Executive Officer John Cullity said, “The acquisition represents an important development in the Group’s growth trajectory as it is the first step in building another significant platform to our Healthcare portfolio.

“Medical device distribution presents a natural adjacency to our existing capability and offers strong economic fundamentals and promising organic growth rates,” Mr Cullity said. “Our strategy is to target specific therapeutic areas focused on ‘personalised healthcare’ which means quicker and more effectivescreening, diagnosis and treatment leading to a better healthcare service for our communities.

“Consistent with our proven strategy we will continue to grow our presence through further bolt-on acquisitions. As a truly independent partner we can provide long term growth opportunities to both existing and new OEM’s as we bring experienced management, capital resources and strong hospital relationships in the Australia and Zealand market,” Mr Cullity added.




--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
nipper
post Posted: Aug 31 2019, 09:44 PM
  Quote Post


Posts: 6,199
Thanks: 2199


QUOTE
EBOS Group has reported “solid growth” in underlying earnings for the past financial year, according to its annual report published on Thursday.

Net profit after tax (NPAT) for the 2019 financial year was $137.7 million (up 0.3% on previous year), while total revenue was $6.9 billion. Underlying results showed NPAT up by 5.2% and EBITDA up by 4.6%, although total revenue saw a small downturn of 0.8%.

It has been a year of “high activity and strategically important for the Group as it has set the foundation for the next wave of growth,” said EBOS Group CEO John Cullity.

“We commenced operations in two brand new facilities in Brisbane and Sydney, providing further warehouse capacity. “We also moved to 100% ownership for TerryWhite Chemmart, signed the Chemist Warehouse Group pharmaceutical contract and retained Blooms The Chemist, one of our largest independent pharmacy group customers,” he says. “These were all great outcomes for our Community Pharmacy division.”

Revenue growth in Community Pharmacy, excluding the impact of lower hepatitis C sales and PBS reforms, was up 3%.

In Australia, Healthcare revenue declined by $183 million (down 3.5%), however excluding the impact of the reduction of hepatitis C sales and the impact of PBS price reforms, revenue increased by 5.2%.

“The Group continues to operate in highly competitive markets and this year was no exception. We have withstood the changing market dynamics and competitive pressures and delivered both solid underlying earnings growth and another strong cash result,” said Mr Cullity.

He added that he was pleased the government, through its recent review into the CSO, had recognised the importance of the wholesale industry in providing Australians with equal access to medicines in accordance with the National Medicines Policy.

“However if the wholesale industry is to maintain its service standards then it requires additional financial support through increased CSO funding and a sustainable wholesale margin,” said Mr Cullity.

“The financial stability of the industry is at a critical juncture with wholesalers being significantly impacted by PBS reforms.

“Approximately 80% of distribution volumes now generate a margin of less than $1 given there has been no effective increase in wholesaler remuneration since 2010. “EBOS, together with other members of the National Pharmaceutical Services Association (NPSA) continues to actively engage with the Federal government and Minister for Health with respect to successfully resolving these matters as part of the negotiation of the upcoming 7th Community Pharmacy Agreement.”

EBOS Group says it is confident of a significant increase in earnings in the financial year 2019-20.

https://ajp.com.au/news/ebos-reports-solid-...lying-earnings/

steady as she goes. My kind of boring. (A Blackie chart, p'raps?)



--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
nipper
post Posted: Jul 2 2018, 05:46 PM
  Quote Post


Posts: 6,199
Thanks: 2199


QUOTE
EBOS has a dual listing on the ASX and the New Zealand Stock Exchange. Mr Cullity said EBOS had invested more than $100 million in highly-automated distribution centres in Sydney, Melbourne and Brisbane to deliver better efficiencies. "The more you can automate the process, the more efficiencies you can drive," Mr Cullity said...
got the Chemist Warehouse gig, off Sigma. $1bill a year.



--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
nipper
post Posted: Jul 31 2016, 05:21 PM
  Quote Post


Posts: 6,199
Thanks: 2199


QUOTE
This Australian wholesaler of a ground-breaking Hepatitis C cure will benefit from the Turnbull government's $1-billion commitment to eradicating the disease over five years. Ebos Group (ASX: EBO) operates a conglomerate business in Australia and New Zealand, where it provides healthcare and animal care products and services. Its core business is in the distribution and supply of medical and pharmaceutical products in Australia and the Asia-Pacific region.

While the business was founded in 1922, its expansion by acquisition only began in the 1990s, and Ebos only reached critical mass in 2007 when it acquired Auckland-based pharmaceutical wholesaler PRNZ.

This was followed in 2013 with the purchase of Symbion, a transaction that elevated Ebos to become the second-largest Australian pharmaceutical wholesaler. This acquisition also accounts for its narrow moat rating.

"The Australian pharmaceutical wholesaler market comprises essentially three players, and is characterised by a high degree of regulation and price-setting by the government through licensing requirements and Medicare," says Chris Kallos, senior equity analyst, Morningstar.

The current excitement around Ebos stems from its involvement in distributing four new Hepatitis C treatments -- Harvoni, Sovaldi, Daklinza and Ibayvr -- which were listed on the Pharmaceutical Benefits Scheme in May.

"They represent medical breakthroughs in this condition, with up to 95 per cent of treated patients cured of Hepatitis C," says Kallos.

The average cost of treatment is estimated at around $100,000, with the estimated number of people affected in Australia pegged at around 230,000. While this is an amazing medical breakthrough and excellent news for those suffering with the condition, Morningstar also believes the buzz is artificially inflating the Ebos share price.

"We consider the shares overvalued and believe this is in part due to the market's overestimation of the impact of a new generation of Hepatitis C drugs on the earnings profile of Ebos," Kallos says. "Despite a current run rate at an industry level of around $200 million per month since listing in May 2016, according to our industry sources, we expect demand to subside over the medium term as patients are cured and the condition eradicated."
- Morningstar



--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
macduffy
post Posted: Feb 20 2014, 08:48 AM
  Quote Post


Posts: 2,379
Thanks: 263


In Reply To: macduffy's post @ Feb 20 2014, 05:21 AM

And a broker's comment on the result.

http://www.stuff.co.nz/business/industries...a-lift-for-Ebos

A company worthy of a bit more attention, IMO. But then, I hold!

smile.gif






 
macduffy
post Posted: Feb 20 2014, 05:21 AM
  Quote Post


Posts: 2,379
Thanks: 263


A good result from EBO for the half year. The acquisition of Symbion appears to be paying off!









 


ShareScene.com
post Posted: Feb 3 2009, 10:00 AM
  Quote Post



Posts: 4,290
Thanks: 206


Company:
EBOS GROUP LIMITED

Code:
EBO

Website
http://www.ebos.co.nz/


 
Lizard
post Posted: Aug 22 2008, 07:44 PM
  Quote Post


Posts: 911
Thanks: 53


Disappointing to see EBO provide so little detail in their reporting today, with profit provided in terms of cps and little other detail by which to judge the quality of result. Neither has the result been posted to their web-site.

My initia

 
 



Back To Top Of Page
Reply to this topic


You agree through the use of ShareCafe, that you understand and accept the TERMS OF USE.


TERMS OF USE  -  CONTACT ADMIN  -  ADVERTISING